Sandeep Kukreja, MD
Pulmonary Disease · Greenwood, INNPI 1992906846
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $156,128 of the $206,165 with a category attached, or 75.7%. Modernatx, Inc. accounts for 71.8% of it on its own, with 43 other manufacturers making up the rest. Reporting peaked in 2023 at $162,028 and has fallen 95.3% since, to $7,588 in 2025. Among pulmonary disease clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 348 payments — averaging $592.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$148K
- Boehringer Ingelheim$50K
- Johnson & Johnson$2K
- Bayer$1K
- GSK$1K
- Olympus Corporation Of The Americas$700
- plus $3K from 38 others
Across 17 payments — averaging $17,513 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$140K
- Modernatx, Inc.$129K
- Actelion Pharmaceuticals, Ltd$18K
- Johnson & Johnson$11K
What the payments were for
- Consulting fees$156,12876%
- Speaking & faculty fees$39,15719%
- Travel & lodging$4,9092%
- Food & beverage$5,9453%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Moderna Covid-19 Vaccine$148,000
- OFEV$12,690
- Adempas$1,324
- Monarch Platform$1,272
- Olympus Bronchoscopes$511
- Olympus Capital Accessories$511
- Olympus Respiratory Accessories$511
- XARELTO$134
- Solitaire$118
How this compares
$206,165 in reported general payments places this provider in the 95th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 58 | $797,169 |
| UptraviSelexipag | 32 | $685,681 |
| OpsumitMacitentan | 46 | $586,279 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 255 | $226,740 |
| OfevNintedanib Esylate | 15 | $219,538 |
| NucalaMepolizumab | 42 | $150,850 |
| EliquisApixaban | 70 | $67,405 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 76 | $51,158 |
| Breo ElliptaFluticasone/Vilanterol | 68 | $38,348 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $25,627 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 36 | $24,419 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 21 | $10,989 |
| Arnuity ElliptaFluticasone Furoate | 11 | $3,924 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $3,718 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,857 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $88 | $1,271,96078 claims |
| BayerAdempas | $1,362 | $797,16958 claims |
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $1,220 | $471,020452 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat | $50,386 | $254,94572 claims |
| PfizerEliquis | $72 | $67,40570 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $334 | $28,48432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Greenwood
- Faisal KhanGreenwood$207K
- Robert DalyGreenwood$54K
- Umar OsmanGreenwood$19K
- Imad ShawaGreenwood$11K
- David MaresAnderson$1.3M
- David WilsonSeymour$689K
- Giovanni InfusinoCrown Point$526K
- Ajay DeshpandeTerre Haute$304K
- Raja DevanathanHobart$193K
- Asaad JandaliMunster$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.